| abstract |
Use of a compound having 50% activity or more of the activity of gastric inhibitory polypeptide, GIP, when tested in the same assay under the same conditions, and/or the use of GIP, analogues and fragments thereof, for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of conditions caused or characterized by abnormal loss of cells and/or for prophylaxis and/or treatment of over weight and obesity. A compound as described above for the prophylaxis and/or treatment of over weight and obesity. Use of antagonists to GIP or the GIP receptor for the prophylaxis and/or treatment of disorders caused or characterized by hyperproliferation of cells and/or abnormally low body weight. |